-
More than 400 dead in DR Congo's spreading Ebola outbreak
-
Albanian clashes as protest over Trump-linked resort boils over
-
Hot spell roasts eastern US as holiday weekend approaches
-
Desire key to Pogacar dominance, says former Tour king Froome
-
Superb Swiatek storms into Wimbledon last 32, Zverev waits
-
Rescuers dig out Venezuelan man eight days after quakes
-
Russian strikes kill 21 in biggest ever attack on Kyiv, mayor says
-
Anderson closes in on record Man City move
-
Swiatek sees off Pliskova to race into Wimbledon third round
-
England change five for South Africa Test
-
Dollar down, stocks shine after disappointing US jobs data
-
Lock Alemanno to make 100th Pumas appearance against Scotland
-
US job growth slows, posing questions for Trump before midterms
-
US posts weaker-than-expected job growth in June
-
Chanel eyes menswear with Charvet shirtmaker takeover
-
UK PM says 'deeply sorry' for decades of forced adoptions
-
Chanel eyes menswear with Charvet shirtmaker takevoer
-
Almost 1.2 mn apply for Spain's migrant regularisation
-
'I grabbed my child': Kyiv residents face devastation of biggest Russian barrage of war
-
Ukrainian state ordered Nord Stream sabotage: German prosecutors
-
Former top jockey Dettori breaks ribs in car crash
-
Swiatek, Zverev aiming to lay down Wimbledon markers
-
Rees-Zammit returns to wing as Wales face Fiji
-
German ruling coalition agrees on major reform package
-
Renovations on historic Paris Opera house extended by three years
-
European stocks climb after Asia rout
-
Thailand denies viral claim Macron knelt before king
-
Former Arsenal, Spain midfielder Cazorla retires
-
Spain, Portugal eye World Cup last 16
-
German drone maker raises $1.2 bn as investors pile into defence
-
Russian strikes kill 17 in biggest ever attack on Kyiv, mayor says
-
French scramble to find air conditioners before next heatwave
-
Uruguay veteran Cavani quits Boca Juniors
-
Japan deploys bear cameras in moutains as attacks surge
-
West Ham's Fernandes joins Spurs
-
Germany's Infineon opens major chip plant as EU seeks tech autonomy
-
Bones of contention: More research needed on 'd'Artagnan corpse'
-
Biggest ever Russian barrage on Kyiv kills at least 13
-
Coffee with a view: tourists flock to Starbucks overlooking North Korea
-
EU top court upholds record 4.1 bn euro Google fine
-
German coalition agrees on reform package in key breakthrough
-
Italy name two debutants to face Japan in Nations Championship opener
-
France recall record try scorer Penaud for All Blacks Test
-
Wallabies' Schmidt rules out another coaching job
-
Seoul's Kospi tanks as Asia tech firms suffer another blow
-
India asks Meta to hold WhatsApp username rollout over fraud fears
-
'Outstanding' Love to start at fly-half for All Blacks against France
-
Deadly Russian barrage on Kyiv kills at least 13
-
Campbell back from four years in Wallabies wilderness to face Ireland
-
Next indirect US-Iran talks after Khamenei funeral: mediators
Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
NEW YORK CITY, NY / ACCESS Newswire / July 2, 2026 / Emerging Growth Research today issued a flash report on OSR Health, Inc. (NASDAQ:OSRH), formerly OSR Holdings, reaffirming its Buy-Emerging rating and 12-month price target of $10.00.
The flash report highlights OSRH's newly announced Shareholder Loyalty Program, a novel plan to reward long-term shareholders with Contingent Value Rights ("CVR") rather than pursuing a reverse stock split. The Company's Board has approved the plan, which remains subject to legal counsel's opinion, with a record date targeted for July 31, 2026.
Key Highlights From the Flash Report:
Shareholder Loyalty Program via Contingent Value Rights:
OSRH plans to distribute one non-transferable CVR for every share held as of the expected record date, at no cost to shareholders. As the Company's share price reaches a series of defined milestones over the 12 months following the record date, shareholders who continuously hold their shares automatically receive additional shares of common stock.
Tiered, Cumulative Reward Structure:
Rewards are delivered in four tiers: at a share price ≥$2.00 sustained for 3 months, a CVR delivers 0.5 additional shares; ≥$3.00 for 6 months delivers 1.0 shares; ≥$4.00 for 9 months delivers 1.5 shares; and ≥$5.00 for 12 months delivers 2.0 shares. A shareholder who remains invested through all four milestones over 12 months would theoretically receive five additional shares per original share, growing their position to six times its original size.
An Alternative to a Reverse Split:
Emerging Growth Research believes the CVR structure is likely the first time a company has used this mechanism to provide an asymmetric upside incentive for shareholders, and views it as preferable to a reverse stock split. Rather than reducing share count and liquidity in a manner that could give short sellers another opportunity to press the stock lower, the program is designed to reward loyal holders with additional shares while potentially improving trading liquidity and discouraging short selling.
Building on the $815 Million BCM Europe Licensing Deal:
The loyalty program builds on the strategic strength of OSRH's $815 million licensing agreement this year with BCM Europe for VXM01. Emerging Growth Research notes that continued execution on the BCM Europe relationship, growth in 4PL, integration of Woori IO's non-invasive glucose monitor into the global wearables market through Big Tech partnerships, and progress in drug candidate development represent substantial sources of potential price upside.
Share Price Dynamics and Potential Floor:
OSRH shares have experienced volatility over the past year. Emerging Growth Research believes a potential floor may now be forming in the stock if short sellers are brought to heel by the new loyalty program's design.
For a copy of the full flash report, please visit:
https://emerginggrowth.com/wp-content/uploads/2026/05/OSRH_Flash-Report_05.05.26.pdf
or
https://emerginggrowth.com/profile/osrh/ (on the right side of the page as you scroll down)
About OSR Health, Inc.
Founded in 2020 and headquartered in Bellevue, Washington, and Gyeonggi-do, South Korea, OSR Health, Inc. (NASDAQ:OSRH), formerly OSR Holdings, is a global healthcare holding company with operations in Korea and Switzerland. The Company has four wholly owned subsidiaries developing oral immunotherapies for the treatment of cancer and biologics for age-related and other degenerative diseases, as well as a diabetes-focused medical device developer advancing non-invasive glucose monitoring technology. OSRH also distributes medical devices and systems and is expanding into 4th party logistics (4PL).
About Emerging Growth Research
Emerging Growth Research is an independent equity research firm providing institutional-quality analysis on emerging and growth-stage companies. The firm delivers ongoing coverage, including Flash Reports on material developments, designed to enhance transparency and broaden investor awareness for companies participating in the Emerging Growth Conference platform.
Contact:
Emerging Growth Research
[email protected]
www.EmergingGrowth.com
Forward-Looking Statements
This press release contains forward-looking statements concerning business operations and financial performance as well as plans, objectives, and expectations for OSR Health, Inc. that are subject to risks and uncertainties. These statements include, but are not limited to, expectations regarding the proposed Shareholder Loyalty Program and its record date, legal counsel's opinion, licensing agreements, regulatory pathways, product development, and capital formation. Actual results may differ materially due to a variety of risks, including the possibility that the CVR program is not implemented as currently contemplated or at all, that non-binding agreements do not result in definitive transactions, that licensing deal milestones may not be realized, regulatory challenges, potential dilution from future financing activities, and financing constraints.

SOURCE: OSR Health, Inc.
View the original press release on ACCESS Newswire
X.Karnes--AMWN